JP2010516235A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516235A5
JP2010516235A5 JP2009545932A JP2009545932A JP2010516235A5 JP 2010516235 A5 JP2010516235 A5 JP 2010516235A5 JP 2009545932 A JP2009545932 A JP 2009545932A JP 2009545932 A JP2009545932 A JP 2009545932A JP 2010516235 A5 JP2010516235 A5 JP 2010516235A5
Authority
JP
Japan
Prior art keywords
qpct
mouse
transgene
human animal
transgenic non
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009545932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/050532 external-priority patent/WO2008087197A1/en
Publication of JP2010516235A publication Critical patent/JP2010516235A/ja
Publication of JP2010516235A5 publication Critical patent/JP2010516235A5/ja
Pending legal-status Critical Current

Links

JP2009545932A 2007-01-19 2008-01-18 アルツハイマー病及び他のqpct関連障害の治療のためのインビボスクリーニングモデル Pending JP2010516235A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88564907P 2007-01-19 2007-01-19
PCT/EP2008/050532 WO2008087197A1 (en) 2007-01-19 2008-01-18 In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders

Publications (2)

Publication Number Publication Date
JP2010516235A JP2010516235A (ja) 2010-05-20
JP2010516235A5 true JP2010516235A5 (enExample) 2011-03-03

Family

ID=39271322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545932A Pending JP2010516235A (ja) 2007-01-19 2008-01-18 アルツハイマー病及び他のqpct関連障害の治療のためのインビボスクリーニングモデル

Country Status (13)

Country Link
US (1) US20080200567A1 (enExample)
EP (2) EP2121944B1 (enExample)
JP (1) JP2010516235A (enExample)
AT (1) ATE521711T1 (enExample)
AU (1) AU2008206936B2 (enExample)
CA (1) CA2675192A1 (enExample)
DK (1) DK2121944T3 (enExample)
ES (1) ES2372229T3 (enExample)
HR (1) HRP20110651T1 (enExample)
NZ (1) NZ578513A (enExample)
SI (1) SI2121944T1 (enExample)
WO (1) WO2008087197A1 (enExample)
ZA (1) ZA200904353B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9277737B2 (en) 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
JP5612860B2 (ja) * 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ[1,5−a]ピリジン誘導体
US9656991B2 (en) * 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8772508B2 (en) * 2007-04-18 2014-07-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8227498B2 (en) * 2007-04-18 2012-07-24 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9034907B2 (en) * 2007-04-18 2015-05-19 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128986A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
WO2008128987A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Novel inhibitors
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
AU2008297070A1 (en) * 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
NZ586665A (en) * 2008-01-14 2011-12-22 Probiodrug Ag MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE (Qpct)
KR101682728B1 (ko) * 2008-07-31 2016-12-05 프로비오드룩 아게 신경변성 질환에 대한 진단적/예후적 지표로서 글루타미닐 사이클라제
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
WO2012022804A1 (en) 2010-08-19 2012-02-23 Probiodrug Ag Crystal structure of glutaminyl cyclase
WO2012028706A1 (en) 2010-09-02 2012-03-08 Probiodrug Ag IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
US8741614B2 (en) 2010-11-02 2014-06-03 Probiodrug Ag Crystal structure of isoglutaminyl cyclase
US20130052203A1 (en) 2011-08-12 2013-02-28 Probiodrug Ag In vivo screening models for treatment of qc-related disorders
EP2879719B1 (en) 2012-08-01 2018-07-04 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
WO2017079547A2 (en) * 2015-11-04 2017-05-11 The Scripps Research Institute Compositions and methods for treating cystic fibrosis
MC200185B1 (fr) 2016-09-16 2017-10-04 Coronal Audio Dispositif et procédé de captation et traitement d'un champ acoustique tridimensionnel
MC200186B1 (fr) 2016-09-30 2017-10-18 Coronal Encoding Procédé de conversion, d'encodage stéréophonique, de décodage et de transcodage d'un signal audio tridimensionnel

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
EP1961416B1 (en) * 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
ATE462432T1 (de) * 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
NZ543146A (en) 2003-05-05 2008-09-26 Probiodrug Ag Use of effectors of glutaminyl cyclase (QC) activity in combination with inhibitors of DP IV or DP IV-like enzymes for the treatment of conditions that can be treated by modulation of QC-and/or DPIV-activity
JP2007509898A (ja) * 2003-11-03 2007-04-19 プロビオドルグ エージー 神経障害治療に有用な組合せ
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
GB0704100D0 (en) 2006-03-17 2007-04-11 Vodafone Plc Improvements in an ehspa architecture
NZ575727A (en) * 2006-09-21 2011-12-22 Probiodrug Ag Novel genes related to glutaminyl cyclase

Similar Documents

Publication Publication Date Title
JP2010516235A5 (enExample)
JP7755699B2 (ja) ヒト化IL-4およびIL-4Rα動物
JP2011501652A5 (enExample)
ES2715949T3 (es) Animales con IL-15 humanizada
HRP20110651T1 (hr) Modeli pretraživanja in vivo radi liječenja alzheimerove bolesti i drugih poremećaja povezanih s qpct
FI3823443T3 (fi) Ditra-taudin jyrsijämallit ja niiden käyttö
JP2011500007A5 (enExample)
Santander et al. Lack of Flvcr2 impairs brain angiogenesis without affecting the blood-brain barrier
JP2011509093A5 (enExample)
JP2020515248A5 (enExample)
Okunomiya et al. Generation of a MOR‐CreER knock‐in mouse line to study cells and neural circuits involved in mu opioid receptor signaling
JP2019505216A5 (enExample)
EP3188600B1 (en) Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
CN103251958B (zh) Men1基因及其编码蛋白的应用
CN114835798B (zh) Cd36基因人源化非人动物的构建方法及应用
US7312079B1 (en) Variants of FAM3C
JPWO2009013794A1 (ja) インスリン分泌誘導剤及び膵臓β細胞増加促進剤
EP2241628B1 (en) Double knockout GABAA alpha 1-/-; CaV3.1 and GABAA alpha 1-/-; Emx1-cre mouse models with enhanced essential tremor
JP2013541938A (ja) アイソqc関連障害の治療のためのインビボスクリーニングモデル
Yan et al. 3.077 Novel PLA2G6 gene mutation is associated with autosomal recessive early-onset parkinsonism
JP2025508063A (ja) アルツハイマー病の野生由来マウスモデル
Laffita et al. 3.075 UNEXPANDED AND INTERMEDIATE POLYMORPHISMS AT SCA2 LOCUS (ATXN2) IN THE CUBAN POPULATION: EVIDENCES ABOUT THE ORIGIN OF EXPANDED ALLELES
Vishwanathan et al. 3.076 AN EARLY ONSET SOUTH INDIAN PARKINSON'S DISEASE PATIENT WITH NOVEL C. 798_799INSA MUTATION-A CASE VIGNETTE
Koziorowski et al. 3.078 THE NOVEL THAP1 GENE MUTATION, CHARACTERIZED BY PHENOTYPICAL HETEROGENEITY
JP2011511622A5 (enExample)